PTCT PTC Therapeutics Inc.

36.01
-0.3  -1%
Previous Close 36.31
Open 36.42
Price To Book 11.11
Market Cap 1672508649
Shares 46,445,672
Volume 1,696,275
Short Ratio 4.54
Av. Daily Volume 1,333,827

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial has commenced - noted October 12, 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest. Further CRL October 25, 2017. Expects to initiate new trial by the end of 2018.
Ataluren
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.
Translarna
Nonsense mutation cystic fibrosis
Noted March 15, 2018 that trial has transitioned into pivotal phase. Updated positive Phase 1 data released June 16, 2018.
RG7916 - FIREFISH
Spinal Muscular Atrophy (SMA) Type 1

Latest News

  1. Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?
  2. Analysts’ Recommendations for PTC Therapeutics in June
  3. Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
  4. Big Biotech Stock Pops and Drops This Week
  5. PTC Therapeutics (PTCT) Jumps: Stock Rises 7.2%
  6. Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
  7. Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back
  8. Don't Get Too Excited About PTC Therapeutics (Yet)
  9. Sarepta's Stock Soars on Encouraging Gene Therapy Results
  10. Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
  11. Biotech Firm Sarepta Surges 40% on Positive Test Results
  12. Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
  13. PTC Therapeutics' Spinal Muscular Atrophy Study Successful
  14. S&P 500’s Top Losses: Why Biogen Declined
  15. Today’s Research Reports on Stocks to Watch: PTC Therapeutics and Catalyst Biosciences
  16. PTC Therapeutics Inc (NASDAQ:PTCT) Is Expected To Breakeven
  17. Why Rent-A-Center, PTC Therapeutics, and Dropbox Jumped Today
  18. Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle
  19. William Blair Upgrades PTC Therapeutics On Risdiplam Prospects
  20. Biogen plunges after rival drug for spinal muscular atrophy shows promise